Date: 2016-09-29
Type of information: Clinical research agreement
Compound: BI 754091 and BI 754111
Company: Boehringer Ingelheim (Germany) Sarah Cannon Research Institute (SCRI) (USA - CO)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: monoclonal antibody/immune checkpoint inhibitor. BI 754091(anti- PD-1) and BI 754111 (anti-LAG 3) are immune checkpoint inhibitors designed to rally the patient’s own immune system to fight cancer. As both compounds interact with the immune system at different points, the combination treatment approach is expected to result in better anti-tumor response, potentially leading to improved outcomes for patients.
Disease: non-small cell lung cancer (NSCLC)
Details: * On September 29, 2016, Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced a new strategic collaboration. The joint clinical development programme will study Boehringer Ingelheim’s BI 754091(anti- PD-1) and BI 754111 (anti-LAG 3) monoclonal antibodies for the combination treatment of multiple cancers with high unmet medical needs, including non-small cell lung cancer (NSCLC). Following preliminary findings, the collaboration could be expanded beyond the initial research focus. Through Sarah Cannon Development Innovations, a full-service, oncology-focused contract research organization (CRO), Sarah Cannon will provide comprehensive clinical development services and operational delivery of Boehringer Ingelheim’s early stage development programs. The collaboration will enable rapid patient enrollment to clinical trials through Sarah Cannon’s extensive network across the U.S. and UK. Sarah Cannon is one of the world’s leading clinical research organizations, conducting more than 220 first-in-human studies to date and enrolling more than 2,000 patients each year on innovative clinical trials.
Financial terms:
Latest news:
